Viewing nowCombinationTelmisartan and Rosuvastatin Tablets 80/10 mg
Telmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Myeongmoon Pharm Co., Ltd.

MFDS item code 202001844 · Approved 2020.03.17 · Insurance code 649807580
Treatment of hypertension; improvement of dyslipidemia; prevention of cardiovascular disease and inhibition of atherosclerosis progression
This medication is used only for patients who need to take both Telmisartan and Rosuvastatin together. Telmisartan reduces the risk of myocardial infarction, stroke, and cardiovascular death in patients over 55 years of age with high risk for cardiovascular disease, in addition to treating essential hypertension. Rosuvastatin lowers blood cholesterol levels in patients with hypercholesterolemia and dyslipidemia, delays the progression of atherosclerosis, and reduces the risk of stroke, myocardial infarction, and vascular interventions due to cardiovascular diseases. By using these two components together, cardiovascular risks due to hypertension and hyperlipidemia can be effectively managed. Therefore, this medication is used for the treatment of patients at risk of cardiovascular disease accompanied by hypertension and dyslipidemia.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each ingredient, telmisartan and rosuvastatin. ○ Telmisartan 1. Essential hypertension Adults: The recommended dose is 40 mg orally once daily as telmisartan; depending on the patient, 20 mg once daily may be effective. If necessary, the dose may be increased to 80 mg once daily. This medicine has an additional blood pressure-lowering effect when administered concomitantly with thiazide diuretics such as hydrochlorothiazide. When the dose is increased, the maximum blood pressure-lowering effect is generally achieved 4 ∼ 8 weeks after starting treatment. 2. Reduction of cardiovascular risk Adults: The recommended dose is 80 mg orally once daily. The risk-reduction effect on cardiovascular morbidity and mortality at doses below 80 mg is not known. When initiating treatment with this medicine to reduce cardiovascular risk, blood pressure monitoring is recommended, and appropriate adjustment of antihypertensive therapy may be necessary. 3. Patients with hepatic impairment Use with caution in patients with mild ∼ moderate hepatic impairment, and do not exceed 40 mg once daily. ○ Rosuvastatin calcium 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined hyperlipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient for most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and patient response; the dose may be increased to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. For patients taking telmisartan and rosuvastatin concomitantly, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
This medication can cause serious harm to the fetus and newborn during pregnancy, so it must be discontinued immediately if pregnancy is confirmed. Women who are pregnant or may become pregnant, and nursing mothers should not take this medication, and it should be used cautiously in fertile women who do not use appropriate contraception. Patients with serious liver or biliary problems, patients with muscle disorders, severe renal impairment, or those taking certain medications should not take this medication. Elderly patients, patients with high potassium levels, and patients with mild to moderate liver impairment require caution when taking this medication. This medication may cause muscle-related side effects such as myalgia, muscle weakness, and rhabdomyolysis, so if muscle pain or weakness occurs during treatment, consult a physician immediately. Regular tests, including liver function tests and blood tests for creatinine and potassium levels, are necessary, and the medication should be discontinued if any abnormalities are found. When taken with other antihypertensives, diuretics, potassium supplements, etc., the risk of side effects may increase due to interactions, so consult with the prescribing doctor. Avoid excessive alcohol consumption during treatment, and be especially cautious if there is a history of liver disease. This medication may cause drowsiness or dizziness, so caution is required when driving or operating machinery. Keep out of reach of children, and it is best not to transfer to another container.
Headache, orthostatic dizziness, sleep paralysis, increased blood pressure, decreased blood pressure, hypotension, ALT elevation, dysuria, rhinitis, pharyngeal discomfort, lung disease, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, urinary tract infection, sepsis, anemia, thrombocytopenia, eosinophilia, hypersensitivity, anaphylactic reactions, hyperkalemia, hypoglycemia, depression, insomnia, anxiety, fainting, visual disturbances, dizziness, bradycardia, tachycardia, dyspnea, abdominal pain, diarrhea, dyspepsia, abdominal bloating, vomiting, abdominal discomfort, dry mouth, abnormal liver function, liver disorders, increased sweating, itching, rash, erythema, vascular edema, drug rash, toxic skin rash, eczema, urticaria, myalgia, low back pain, muscle cramps, arthralgia, limb pain, tendon pain, acute kidney failure, chest pain, weakness, influenza-like illness, increased serum creatinine, increased uric acid in blood, elevated liver enzymes, increased serum CK, decreased hemoglobin, vascular edema, hypovolemia, hypersensitivity reactions including vascular edema, diabetes, headache, dizziness, constipation, nausea, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, hypersensitivity drug reaction syndrome with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, blood pressure lowering, syncope due to blood pressure lowering, loss of consciousness, shock, liver dysfunction, jaundice, anaphylaxis-like symptoms, interstitial pneumonia, rhabdomyolysis, palpitations, fatigue, nausea, insufficient effect, facial spasms, sensory abnormalities, paralysis, hyperventilation, pneumonia, flushing, erectile dysfunction, loss of appetite, arrhythmia, weakness, edema, decreased libido, facial edema, alopecia, conjunctivitis, ringing in the ears, petechiae, thrombocytopenia, increased serum creatinine, acute kidney failure, oliguria
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in an airtight container to protect it from air and moisture. It is recommended to maintain a storage temperature between 1 and 30 degrees Celsius.
Bright blue oval film-coated tablets
30 tablets/box [(10 tablets/PTP*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Myeongmoon Pharm Co., Ltd.
CombinationTelmisartan 80mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhannanghang Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Yuhan Corporation Co., Ltd.
CombinationTelmisartan 40mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 80mg · Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication · Combination
Yuhan Corporation
CombinationTelmisartan 40mg · Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication · Combination
Ildong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.